InspireMD (NSPR) Stock Price

InspireMD Price

NYSE AMEX·CLOSED
0.64
​
Market closed

Over the last 17 years InspireMD grew revenue by 5.9% annually, reaching 8.98 M USD. For InspireMD, the net margin of -543.3% is down versus -331.9% a few years ago.

InspireMD stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InspireMD business model & stock analysis

InspireMD, Inc. generates revenue through the commercialization of its MicroNet stent platform technology, which includes the MicroNet micron mesh sleeve for embolic protection during stenting procedures. The company markets the CGuard carotid embolic prevention system (CGuard EPS), combining MicroNet with a self-expandable nitinol stent for carotid artery applications, and the MGuard Prime Embolic Protection System (MGuard Prime EPS) for acute coronary syndromes and saphenous vein graft interventions. In the European Union, InspireMD sells MGuard Prime EPS, a bare-metal cobalt-chromium stent, for coronary disease treatment. The company is also developing the neurovascular flow diverter NGuard for endovascular use. The primary buyers of InspireMD's products are healthcare providers, including hospitals and clinics specializing in vascular and coronary interventions. These institutions purchase the MicroNet, CGuard EPS, and MGuard Prime EPS to enhance procedural safety and outcomes during stent implantation. The European Union represents a key market for the MGuard Prime EPS, where it is marketed as a treatment option for coronary disease. The company's development of NGuard indicates a strategic focus on expanding its product portfolio into neurovascular applications. InspireMD's product segments are defined by clinical applications: carotid artery procedures (CGuard EPS), acute coronary syndromes (MGuard Prime EPS), and coronary disease treatment (MGuard Prime EPS in the EU). The MicroNet technology serves as a foundational component across multiple product lines, providing embolic protection. The company's revenue streams are driven by direct sales of these medical devices to healthcare institutions, with the EU market being a significant commercial focus for MGuard Prime EPS.

Frequently asked questions about InspireMD

9 analysts currently rate the InspireMD stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect InspireMD to generate revenue of 9.80 M USD and earnings per share of -0.35 USD.

Converted at the current exchange rate, the InspireMD share trades at 0.58 EUR (0.64 USD).

The InspireMD share (NSPR) is listed on 2 stock exchanges, including: NASDAQ (NSPR).

The expected revenue of InspireMD is 9.80 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of InspireMD is -25.72 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of InspireMD is currently -1.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the InspireMD stock.

The price-to-sales ratio (P/S) of InspireMD is currently 4.79. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the InspireMD stock.

The Eulerpool Quality Score for InspireMD is 6/10.

The ISIN of InspireMD is US45779A8466. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of InspireMD is A2PGJ7. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of InspireMD is NSPR. The ticker symbol is used to trade InspireMD shares on the stock exchange.

Fair ValueTerminal
0.54 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
70,700.79 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Israel
Currency
USD
Initial public offering
Apr 12, 2013
ISIN
US45779A8466
Cusip
45779A853
Sedol
BJXML68
Market capitalization
26.77 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-1.82
P/Ee 2027
-2.31
P/Ee 2028
—
P/S
P/Se
4.79
EV/EBIT
—
P/B Ratio
0.48
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-83.41 %
Last updated Nov 20, 2026, 12:42 AM

InspireMD Ticker

AMEX · NSPRNASDAQ · NSPR

All fundamentals and in-depth analysis of InspireMD

Our stock analysis for InspireMD stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InspireMD. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.